Product will provide robust, standardised tool for study and screening of potential treatments for motor neuron diseases.
06.12.2023
UK Science Minister Andrew Griffith MP opens bit.bio expanded labs
Minister Griffith cut the ribbon to officially open bit.bio’s manufacturing and automation labs for the consistent and scalable pr...
New collaboration to develop multi-cell models of the human brain
King's College London & bit.bio collaborate to develop multi-cell models of the human brain with optimised open-source protocols f...
bit.bio CEO wins in 2 categories at Great British Entrepreneur Awards
Mark Kotter wins in two categories, Equity-Backed Entrepreneur of the Year and Purpose Entrepreneur of the Year, at the Great Brit...
bit.bio cell therapy pipeline featured in Endpoints News
Endpoints News did an exclusive interview with bit.bio's CEO after the cell therapy pipeline announcement with an initial focus on...
Life Sciences: Invent podcast on cell and gene therapies
This episode of the Invent podcast features our director of cellular phenotyping Davide Danovi discussing innovations in cell ther...
.png)
bit.bio unveils cell therapy pipeline, lead candidate and expanded SAB
Lead candidate is encapsulated allogeneic txHepatocytes for treatment of acute liver failure, SAB expanded to include 3 global exp...
Product launch | CRISPR-Ready ioGlutamatergic Neurons
bit.bio launches first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease m...
bit.bio named as one of the WIRED Trailblazers in Cambridge
WIRED have named 16 Trailblazer companies in Cambridge that are pushing boundaries and scaling up - including bit.bio.